ASMB Insider Trading

Insider Ownership Percentage: 5.10%
Insider Buying (Last 12 Months): $307,413.96
Insider Selling (Last 12 Months): $87,218.83

Assembly Biosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Assembly Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

Assembly Biosciences Share Price & Price History

Current Price: $9.31
Price Change: Price Decrease of -0.16 (-1.69%)
As of 04/3/2025 05:00 PM ET

This chart shows the closing price history over time for ASMB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$9.31Closing price on 04/03/25:

SEC Filings (Institutional Ownership Changes) for Assembly Biosciences (NASDAQ:ASMB)

19.92% of Assembly Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ASMB by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$23Mbought$11ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M-$10M$0$10M$20MTotal InflowsTotal Outflows
Assembly Biosciences logo
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Read More on Assembly Biosciences

Today's Range

Now: $9.31
Low: $9.05
High: $9.98

50 Day Range

MA: $12.13
Low: $9.31
High: $14.77

52 Week Range

Now: $9.31
Low: $9.04
High: $19.93

Volume

24,533 shs

Average Volume

24,957 shs

Market Capitalization

$69.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Who are the company insiders with the largest holdings of Assembly Biosciences?

Assembly Biosciences' top insider investors include:
  1. Alexander Schornstein (Major Shareholder)
  2. John G Mchutchison (Director)
  3. Jason A Okazaki (CEO)
  4. Nicole S White (Insider)
  5. Jeanette M Bjorkquist (Insider)
  6. Michael Houghton (Director)
Learn More about top insider investors at Assembly Biosciences.